GleamWall
中文EN

PAVM PAVmed Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1624326 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY410.3%
TTM net income YoY-693.3%
TTM EPS YoY—
Revenue 3-yr CAGR-54.7%
Net income 3-yr CAGR—

Margins

Gross margin-212.2%
Operating margin-19,315.5%
Net margin-12,406.8%
FCF margin-3,024.3%
EBITDA margin-19,264.2%

Returns

ROE-61.2%
ROA-50.1%
ROIC (approx.)-84.8%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets71.2%
Debt / equity0.00x
Current ratio0.41x
Interest coverage-5,717.40x

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-38.1%
Payout ratio—
Capex / revenue38.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$41,000$33,000$22,000$52,000$5,000$6,000$8,000$10,000
Cost of revenue$158,000$122,000$97,000$85,000$55,000$41,000$36,000$48,000
Gross profit-$117,000-$89,000-$75,000-$33,000-$50,000-$35,000-$28,000-$38,000
R&D expense$1.92M$2.07M$1.39M$1.83M$1.09M$790,000$787,000$807,000
SG&A expense$4.48M$4.65M$6.36M$4.69M$3.50M$3.67M$4.38M$4.19M
Operating income-$6.73M-$7.02M-$8.04M-$6.80M-$4.84M-$4.71M-$5.45M-$5.19M
Interest expense$5,000$2,000$3,000-$5,000$8,000$4,000$4,000$7,000
Pretax income-$13.04M-$6.60M-$1.06M-$2.76M-$6.01M-$12.32M$18.62M$1.14M
Income tax$0$0$0$0$0$0$0—
Net income-$11.65M-$5.38M-$60,000-$1.26M-$5.38M-$11.92M$18.97M$1.43M
EBITDA-$6.71M-$7.00M-$8.02M-$6.79M-$4.82M-$4.69M-$5.40M-$5.12M
EPS (basic)-1.77-0.87-4.42—-8.81-22.0838.26—
EPS (diluted)—-0.87-4.42—-0.29-22.0810.10—
Weighted avg. shares (diluted)—6.27M1.58M—21.55M602,8221.75M—
Balance sheet
Cash & equivalents$3.63M$3.78M$6.46M$1.24M$3.10M$4.00M$2.70M$1.19M
Receivables$31,000$16,000$21,000$15,000$3,000$3,000$9,000$18,000
Current assets$9.68M$4.86M$7.41M$2.26M$4.19M$5.49M$3.64M$2.16M
PP&E, net$62,000$73,000$79,000$77,000$81,000$100,000$114,000$151,000
Total assets$35.21M$40.21M$45.42M$38.81M$38.07M$43.89M$52.82M$30.66M
Current liabilities$23.80M$4.09M$3.66M$14.84M$10.46M$10.51M$9.78M$35.45M
Total liabilities$25.08M$20.91M$20.43M$16.51M$12.28M$12.47M$11.89M$37.69M
Shareholders' equity$27.45M$35.05M$39.52M$33.97M$32.52M$37.53M$44.99M-$2.50M
Shares outstanding6.95M6.27M6.27M927,93423.05M20.14M16.77M373,300
Cash flow statement
Operating cash flow$2.42M-$2.66M-$2.62M-$1.55M-$896,000-$1.18M-$1.58M$94,000
Capital expenditure$8,000$13,000$22,000$14,000$3,000$8,000$6,000$4,000
Free cash flow$2.41M-$2.68M-$2.64M-$1.56M-$899,000-$1.19M-$1.59M$90,000
Investing cash flow-$8,000-$13,000-$22,000-$14,000-$3,000-$8,000-$6,000-$4,000
Financing cash flow$2.74M$0$7.56M$0-$2,000$2.49M$3.10M$330,000
Depreciation & amortization$19,000$19,000$20,000$18,000$22,000$22,000$43,000$69,000
Stock-based compensation$967,000$917,000$182,000$232,000$383,000$162,000$930,000$733,000

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.